| __timestamp | Geron Corporation | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 612613000000 |
| Thursday, January 1, 2015 | 17793000 | 650773000000 |
| Friday, January 1, 2016 | 18761000 | 619061000000 |
| Sunday, January 1, 2017 | 19287000 | 628106000000 |
| Monday, January 1, 2018 | 18707000 | 717599000000 |
| Tuesday, January 1, 2019 | 20893000 | 964737000000 |
| Wednesday, January 1, 2020 | 25678000 | 875663000000 |
| Friday, January 1, 2021 | 29665000 | 886361000000 |
| Saturday, January 1, 2022 | 43628000 | 997309000000 |
| Sunday, January 1, 2023 | 69135000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Cracking the code
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Takeda Pharmaceutical Company Limited and Geron Corporation have showcased contrasting approaches. Takeda, a global leader, has consistently reported SG&A expenses in the range of $600 billion to over $1 trillion annually, reflecting its expansive operations. In contrast, Geron, a smaller biotech firm, has maintained a more modest SG&A expenditure, peaking at approximately $69 million in 2023.
From 2014 to 2023, Takeda's SG&A expenses grew by about 72%, while Geron's increased by over 300%, albeit from a much smaller base. This disparity highlights the different scales and strategies of these companies. As we look to 2024, Takeda's data remains consistent, while Geron's is notably absent, leaving room for speculation on its future trajectory.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited and Geron Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Geron Corporation
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs Geron Corporation
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Geron Corporation
Geron Corporation or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?